Buscar
Alnylam Pharmaceuticals Inc
ALNYAñadir a la lista de seguimiento
198.435USD
-88.185-30.77%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
26.27BCap. mercado
48.57P/E TTM
Más Datos de Alnylam Pharmaceuticals Inc Compañía
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Información de Alnylam Pharmaceuticals Inc
Símbolo de cotizaciónALNY
Nombre de la empresaAlnylam Pharmaceuticals Inc
Fecha de salida a bolsaMay 28, 2004
Director ejecutivoGreenstreet (Yvonne L)
Número de empleados2230
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 28
Dirección675 W Kendall St
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142-1168
Teléfono16175518200
Sitio Webhttps://www.alnylam.com/
Símbolo de cotizaciónALNY
Fecha de salida a bolsaMay 28, 2004
Director ejecutivoGreenstreet (Yvonne L)
Ejecutivos de Alnylam Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
671.00
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Alnylam Pharmaceuticals Inc?
Los cinco principales accionistas de Alnylam Pharmaceuticals Inc son: Dr. Yvonne L. Greenstreet, M.D.
¿Cuántas instituciones poseen acciones de Alnylam Pharmaceuticals Inc (ALNY)?
A fecha de 2026Q1, 1634 instituciones poseen acciones de Alnylam Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 133.66M, lo que representa el 100.11% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -6052832.00.
¿Cuál es la mayor fuente de ganancias de Alnylam Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial AMVUTTRA generó la ganancia más alta para Alnylam Pharmaceuticals Inc, ascendiendo a 2.31B y representando el 62.30% de la ganancia total.